The scope of the guideline is urate-lowering therapy in patients with chronic kidney disease (not on dialysis) without symptomatic hyperuricemia (such as gout and/or uric acid stone formation). The guideline does not make recommendations about the management of uric-acid kidney stones or gout in people w...
The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating people with diabetes and CKD. ...
Fabry disease (FD) is a genetic disease, with X-chromosome linked inheritance, due to variants in the GLA gene that encodes the α-galactosidase A (α-GAL) enzyme. The purpose of the present study was to create a consensus aiming to standardize the recommendations regarding the renal involvement of FD wi...
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease
(CKD). It aims to prevent or delay the progression, and reduce the risk of complications and
cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with
CKD.
NICE has produce...
Cheung, Alfred;
Chag, Tara;
Cushman, William;
Furth, Susan;
Hou, Fan;
Ix, Joachim;
Knoll, Gregory;
Muntner, Paul;
Pecoits-Filho, Roberto;
Sarnak, Mark;
Tobe, Sheldon;
Tomson, Charles;
Lytvyn, Lyubov;
Craig, Jonathan;
Tunnicliffe, David;
Howell, Martin;
Tnoelli, Marcelo;
Cheung, Michael;
Earley, Amy;
Mann, Johannes.
The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis represents an update to the KDIGO 2012 guideline on this topic. Development of this guideline update followed a rigorou...
The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources....
Lok, Charmaine E;
Huber, Thomas S;
Lee, Timmy;
Shenoy, Surendra;
Yevzlin, Alexander S;
Abreo, Kenneth;
Allon, Michael;
Asif, Arif;
Astor, Brad C;
Glickman, Marc H;
Graham, Janet;
Moist, Louise M;
Rajan, Dheeraj K;
Roberts, Cynthia;
Vachharajani, Tushar J;
Valentini, Rudolph P.
The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) has provided evidencebased guidelines for hemodialysis vascular access since 1996. Since the last update in 2006, there has been a
great accumulation of new evidence and sophistication in the guidelines process. The 201...
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications....
This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5....
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma
and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people
with myeloma by promoting the most effective tests and treatments for myeloma and its
complications....
